Risk Factors Update Summary
- Addition of potential drug price negotiation under the IRA may impact pricing strategies significantly.
- Expansion of large molecule production capacity by building a new gene therapy manufacturing facility.
- Increased focus on cybersecurity threats, including AI and machine learning, with higher ransom demands.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=875045&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.